Wednesday, May 03, 2023 9:38:14 AM
Bearish
Recent ASND News
- Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024 • GlobeNewswire Inc. • 06/24/2024 08:45:36 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/12/2024 08:01:51 PM
- Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference • GlobeNewswire Inc. • 06/04/2024 08:01:00 PM
- Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024 • GlobeNewswire Inc. • 06/03/2024 08:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/31/2024 08:26:57 PM
- Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024 • GlobeNewswire Inc. • 05/30/2024 12:30:00 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/29/2024 08:08:49 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/16/2024 08:01:58 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/14/2024 06:37:58 PM
- Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism • GlobeNewswire Inc. • 05/14/2024 06:31:44 PM
- Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial • GlobeNewswire Inc. • 05/13/2024 12:30:00 PM
- Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024 • GlobeNewswire Inc. • 05/09/2024 12:30:00 PM
- Ascendis Pharma Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/02/2024 08:01:00 PM
- Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024 • GlobeNewswire Inc. • 04/25/2024 08:46:31 PM
- United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism • GlobeNewswire Inc. • 04/24/2024 12:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/07/2024 04:31:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2024 02:39:29 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 01:14:23 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 01:04:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 12:37:04 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 08:17:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 08:07:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 07:54:21 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 07:36:16 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM